Skip to search formSkip to main contentSkip to account menu

SB 239063

Known as: SB-239063 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ImidazolesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Role of p38 MAP kinase in postcapillary venule leukocyte adhesion induced by ischemia/reperfusion injury.
2005
2005
Inhibition of p 38 reduces myocardial infarction injury in the mouse but not pig after ischemia-reperfusion
Kaiser, Robert A., Jefferson M. Lyons, Jodie Y. Duffy, Connie J. Wagner, Kelly M. McLean, Timothy P. O’Neill, Jeffrey M. Pearl… 
Highly Cited
2002
Highly Cited
2002
The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury.
2002
2002
The selective p 38 inhibitor SB-239063 protects primary neurons from 2 mild to moderate excitotoxic injury 3
5 In Vivo Pharmacology, High Throughput Biology, Discovery Research, GlaxoSmithKline, PO Box 1539, Mail Code UW 2523, 709… 
2001
2001
SB-239063, a Potent and Selective Inhibitor of P38 Map Kinase: Preclinical Pharmacokinetics and Species-Specific Reversible Isomerization
AbstractPurpose. A series of studies was conducted to evaluate the preclinical pharmacokinetics of SB-239063 (trans-1-(4… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)